Navigation Links
Targeting use of acid-suppressants in hospital patients
Date:1/7/2013

Gastrointestinal bleeds which occur in the hospital, although rare, are a significant source of morbidity and mortality when they occur. Currently, the prophylactic use of acid-suppressive medication in non-critically ill patients in the hospital is not widely recommended. Despite this, these medications continue to be widely utilized for this purpose.

Shoshana Herzig from the Beth Israel Deaconess Medical Center in Massachusetts, USA, and her colleagues believe that there is a group of patients whose risk of gastrointestinal bleeds is high enough to warrant the routine prescription of acid-suppressive medication, and a larger group in whom these medications can be safely withheld. The new study, which has developed a risk scoring system to identify these patients, appears online in the Journal of General Internal Medicine, published by Springer.

Recent studies have found that the risk of gastrointestinal bleeding in hospitalized, non-critically ill patients is fairly low. However, some patients will be at greater risk for this complication than others and there is currently no method available to medical staff to help identify those most likely to have a gastrointestinal bleed. The authors therefore set out to find any potential factors which might identify which patients were most at risk to help target the use of prophylactic acid-suppressive medication where it is necessary, and withhold such medication in the rest.

Herzig and her colleagues studied 75,723 admissions to a large academic medical center over a three-year period. Patients were excluded from analysis if they were admitted with gastrointestinal bleeding, developed a bleed within one day of admission, or were due to have cardiac catheterization. There were gastrointestinal bleeds in a total of 203 patients.

From their analysis, Herzig and her colleagues identified independent risk factors which increased the likelihood of a gastrointestinal bleed. These were being over 60 years of age; being male; having liver disease, acute renal failure, or sepsis; being on a medicine service; already taking prophylactic anticoagulants; and having clotting disorders. This information then enabled the authors to develop a risk scoring system to identify high-risk groups. They found that risk of bleeding increased directly in line with these clinical risk factors.

The authors emphasize the need for further studies to reproduce this data. However, their scoring system allows identification of a sub-set of patients who may benefit from prophylactic use of acid-suppressive medication, as well as a larger group in whom these medications can safely be avoided. They conclude that "with further validation at other medical centers, this scoring system may help clinicians individualize the decision to prescribe acid-suppressive medication as prophylaxis."


'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

Related medicine news :

1. Spread of cancer cells may be slowed by targeting of protein
2. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
3. Salmonella spreads by targeting cells in our gut, study shows
4. Targeting neurotransmitter may help treat gastrointestinal conditions
5. Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model
6. Targeting inflammation to treat depression
7. Targeting inflammation to prevent, treat cancers
8. New targeting technology improves outcomes for patients with atrial fibrillation
9. IBN discovers human neural stem cells with tumor targeting ability
10. Scientists tailor cell surface targeting system to hit organelle ZIP codes
11. Study provides guidance for use of acid-suppressive medications in hospital patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed ... an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show ... Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and development and ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology: